Navigation Links
Watson Launches Generic LIPITOR®
Date:11/30/2011

PARSIPPANY, N.J., Nov. 30, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR® (atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc.  Watson began shipping the product today.  LIPITOR® is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.

Under the terms of the exclusive supply and distribution agreement, Pfizer manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States. Pfizer will receive a share of the net sales from Watson's sales of the product. The agreement runs until November 30, 2016. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending September 30, 2011, LIPITOR® had sales of approximately $7.8 billion, according to IMS Health data.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/53424-watson-pharmaceuticals-launches-generic-lipitor

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LIPITOR® is a registered trademark of Pfizer Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

 CONTACTS:Investors: 

Patty Eisenhaur 

(862) 261-8141 

 

Media: 

Charlie Mayr 

(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Those who may ... can find some useful information in a new video released by Serenity Recovery, ... which can be viewed on the Serenity Recovery YouTube channel, examines various treatment ...
(Date:5/2/2016)... Boulder, Colorado (PRWEB) , ... May 02, 2016 ... ... Chips, is continuing its traditions of innovation by partnering with college students at ... Jared Levy, led the CU-Boulder senior level advertising campaigns class in the School ...
(Date:5/2/2016)... , ... May 02, 2016 , ... In honor of ... offer an incentive to people who share their fitness journey on social media. ... first aid products, will award a $100 product voucher each week during May to ...
(Date:5/2/2016)... , ... May 02, 2016 , ... East Los Angeles ... extractions. Currently, patients can visit Dr. Assili to receive any dental extraction treatment for ... and it expires June 30, 2016. With the lower price, patients can more easily ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):